VAN ANDEL RESEARCH INSTITUTE: Form 990, tax year 2019
View the entire original 990 at ProPublica ↗
- Organization
- VAN ANDEL RESEARCH INSTITUTE (EIN 52-2000823)
- Tax period
- 2019-12-01 to 2020-11-30
- Filed
- 2021-10-14
- IRS object ID
- 202112879349302036
- Schema version
- 2019v5.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule K
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2021-10-14T15:17:56-05:00 | ReturnTs |
| Tax Period End | 2020-11-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 861065772 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | DELOITTE TAX LLP | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 50 SOUTH SIXTH STREET SUITE 2800 | AddressLine1Txt |
| City | MINNEAPOLIS | CityNm |
| State Abbreviation | MN | StateAbbreviationCd |
| ZIP | 55402 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2019-12-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 522000823 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | VAN ANDEL RESEARCH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | VANA | BusinessNameControlTxt |
| Phone | 6162345000 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 49503 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | TIMOTHY J MYERS | PersonNm |
| Person Title | VICE PRESIDENT & CFO | PersonTitleTxt |
| Phone | 6162345368 | PhoneNum |
| Signature | 2021-10-14 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | ANNE FULTON | PreparerPersonNm |
| PTIN | P00941863 | PTIN |
| Phone | 6123974000 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2019 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | TIMOTHY J MYERS | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 49503 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $89,082,168 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.VAI.ORG | WebsiteAddressTxt |
| Type Of Organization Trust | Yes (X) | TypeOfOrganizationTrustInd |
| Formation | 1996 | FormationYr |
| Legal Domicile State | MI | LegalDomicileStateCd |
| Activity Or Mission | MEDICAL RESEARCH ORGANIZATION | ActivityOrMissionDesc |
| Voting Members Governing Body | 6 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 5 | VotingMembersIndependentCnt |
| Total Employee | 525 | TotalEmployeeCnt |
| Total Volunteers | 12 | TotalVolunteersCnt |
| Total Gross UBI | $228,355 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $74,898,909 | PYContributionsGrantsAmt |
| CY Contributions Grants | $79,336,784 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $1,879,646 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $845,797 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,317,104 | PYInvestmentIncomeAmt |
| CY Investment Income | $445,632 | CYInvestmentIncomeAmt |
| PY Other Revenue | $8,264,369 | PYOtherRevenueAmt |
| CY Other Revenue | $8,263,465 | CYOtherRevenueAmt |
| PY Total Revenue | $86,360,028 | PYTotalRevenueAmt |
| CY Total Revenue | $88,891,678 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $2,433,098 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,413,493 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $45,621,394 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $47,981,506 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $782,420 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $51,587,236 | PYOtherExpensesAmt |
| CY Other Expenses | $44,034,771 | CYOtherExpensesAmt |
| PY Total Expenses | $99,641,728 | PYTotalExpensesAmt |
| CY Total Expenses | $94,429,770 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$13,281,700 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$5,538,092 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $274,298,502 | TotalAssetsBOYAmt |
| Total Assets EOY | $289,629,145 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $405,586,337 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $453,494,619 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | -$131,287,835 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | -$163,865,474 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | MEDICAL RESEARCH ORGANIZATION VAN ANDEL RESEARCH INSTITUTE IS AN INDEPENDENT BIOMEDICAL RESEARCH ORGANIZATION COMMITTED TO IMPROVING THE HEALTH AND ENHANCING THE LIVES OF CURRENT AND FUTURE GENERATIONS. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $12,400,365 | ExpenseAmt |
| Grant | $333,513 | GrantAmt |
| Revenue | $354,554 | RevenueAmt |
| Desc | CENTER FOR CANCER AND CELL BIOLOGY SCHEDULE O PROVIDES FURTHER INFORMATION REGARDING THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $13,204,828 | ExpenseAmt |
| Grant | $2,003,389 | GrantAmt |
| Revenue | $84,102 | RevenueAmt |
| Desc | CENTER FOR EPIGENETICSSCHEDULE O PROVIDES FURTHER INFORMATION REGARDING THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $8,118,583 | ExpenseAmt |
| Grant | $53,646 | GrantAmt |
| Revenue | $13,194 | RevenueAmt |
| Desc | CENTER FOR NEURODEGENERATIVE SCIENCESEE SCHEDULE O FOR FURTHER INFORMATION ABOUT THIS PROGRAM'S ACCOMPLISHMENTS. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $31,117,369 | ExpenseAmt |
| Grant | $22,945 | GrantAmt |
| Revenue | $393,947 | RevenueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $31,117,369 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $22,945 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $393,947 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $64,841,145 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | Yes (1) | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | Yes (1) | TaxExemptBondsInd |
| Invest Tax Exempt Bonds | 0 | InvestTaxExemptBondsInd |
| Escrow Account | 0 | EscrowAccountInd |
| On Behalf Of Issuer | 0 | OnBehalfOfIssuerInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | Yes (1) | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 105 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 525 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 6 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 5 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TIMOTHY J MYERS VP & CFO | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6162345368 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 333 BOSTWICK AVENUE NE | AddressLine1Txt |
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
| ZIP | 495032518 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (16 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DAVID VAN ANDEL | |||||||||
| CHAIRMAN / CEO | 36.00 | 17.00 | Yes (X) | Yes (X) | $520,256 | $0 | $156,846 | ||
| DR GEORGE VANDE WOUDE | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $9,000 | $0 | $0 | |||
| DR JAMES FAHNER | |||||||||
| TRUSTEE | 1.00 | 1.00 | Yes (X) | $7,000 | $2,200 | $0 | |||
| DR MAX WICHA | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $13,000 | $0 | $0 | |||
| DR MICHELLE LEBEAU | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $8,000 | $0 | $0 | |||
| DR TOM DEMEESTER | |||||||||
| TRUSTEE | 1.00 | 0.00 | Yes (X) | $9,000 | $0 | $0 | |||
| DR JANA HALL | |||||||||
| CHIEF OPERATIONS OFFICER | 52.00 | 1.00 | Yes (X) | $463,709 | $0 | $145,389 | |||
| TIMOTHY MYERS | |||||||||
| V.P. & CHIEF FINANCIAL OFFICER | 50.00 | 3.00 | Yes (X) | $344,197 | $0 | $99,590 | |||
| DR PETER JONES | |||||||||
| CHIEF SCIENTIFIC OFFICER & RES. DIR. | 52.00 | 1.00 | $752,533 | $0 | $235,728 | Yes (X) | |||
| THOMAS CURRAN JR | |||||||||
| GENERAL COUNSEL | 50.00 | 3.00 | $276,743 | $0 | $80,596 | Yes (X) | |||
| GERALD CALLAHAN | |||||||||
| CHIEF STRATEGIC OFFICER | 51.00 | 2.00 | $381,738 | $0 | $125,592 | Yes (X) | |||
| KATHY VOGELSANG | |||||||||
| CHIEF INVESTMENT OFFICER | 45.00 | 0.00 | $742,294 | $0 | $438,840 | Yes (X) | |||
| DR PATRIK BRUNDIN | |||||||||
| ASSOCIATE RESEARCH DIRECTOR | 45.00 | 0.00 | $529,770 | $0 | $117,375 | Yes (X) | |||
| DR PETER LAIRD | |||||||||
| DISTINGUISHED INVESTIGATOR | 45.00 | 0.00 | $431,975 | $0 | $74,632 | Yes (X) | |||
| TED HEILMAN | |||||||||
| ASSOC DIRECT-SR. PORTFOLIO MGR. | 45.00 | 0.00 | $418,301 | $0 | $262,994 | Yes (X) | |||
| DR GERD PFEIFER | |||||||||
| SR. SCIENTIFIC INVESTIGATOR | 45.00 | 0.00 | $384,927 | $0 | $47,603 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,292,443 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $2,200 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $1,785,185 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 96 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| HOGAN LOVELLS US LLP | |||||
| COLUMBIA SQUARE 555 THIRTEENTH ST | WASHINGTON | DC | 20004 | ATTORNEY SERVICES | $523,385 |
| DE LAGE LANDEN FIN SVCS INC | |||||
| 1111 OLD EAGLE SCHOOL ROAD | WAYNE | PA | 19087 | FINANCING SERVICES | $359,793 |
| ALLIED UNIVERSAL SECURITY SVCS | |||||
| PO BOX 828854 | PHILADELPHIA | PA | 191828854 | SECURITY SERVICES | $301,714 |
| SECURALARM SYSTEMS INC | |||||
| 112 54TH STREET SW | GRAND RAPIDS | MI | 49548 | SECURITY SERVICES | $190,424 |
| ANDY J EGAN COMPANY INC | |||||
| 2001 WALDORF NW STE 200 | GRAND RAPIDS | MI | 49544 | MAINTENANCE SERVICES | $189,566 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 17 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $88,428 | FundraisingAmt |
| Related Organizations | $54,223,134 | RelatedOrganizationsAmt |
| Government Grants | $18,537,976 | GovernmentGrantsAmt |
| All Other Contributions | $6,487,246 | AllOtherContributionsAmt |
| Noncash Contributions | $22,142 | NoncashContributionsAmt |
| Total Contributions | $79,336,784 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | RESEARCH BILLED REV | Desc |
| Business | 541700 | BusinessCd |
| Total Revenue Column | $845,797 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $624,920 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $220,877 | UnrelatedBusinessRevenueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $845,797 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $414,114 | TotalRevenueColumnAmt |
| Exclusion | $414,114 | ExclusionAmt |
Royalties Revenue RoyaltiesRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $26,392 | TotalRevenueColumnAmt |
| Exclusion | $26,392 | ExclusionAmt |
Gross Rents GrossRentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $108,000 | RealAmt |
Less Rental Expenses LessRentalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | $109,961 | RealAmt |
Rental Income Or Loss RentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Real | -$1,961 | RealAmt |
Net Rental Income Or Loss NetRentalIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$1,961 | TotalRevenueColumnAmt |
| Exclusion | -$1,961 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $38,500 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $6,982 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other | $31,518 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $31,518 | TotalRevenueColumnAmt |
| Exclusion | $31,518 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $7,712 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $88,428 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $56,986 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$49,274 | TotalRevenueColumnAmt |
| Exclusion | -$49,274 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $9,259 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $12,920 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$3,661 | TotalRevenueColumnAmt |
| Exclusion | -$3,661 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Sales Of Inventory | $11,896 | GrossSalesOfInventoryAmt |
| Cost Of Goods Sold | $3,641 | CostOfGoodsSoldAmt |
Net Income Or Loss NetIncomeOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $8,255 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $777 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $7,478 | UnrelatedBusinessRevenueAmt |
Other Revenue Misc OtherRevenueMiscGrp (3 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| ALLOCATED ADMIN. EXP. | 561000 | $7,725,025 | $7,725,025 |
| GAIN ON C3 ACQUISIT. | 900099 | $213,714 | $213,714 |
| REIMBURSED EXPENSES | 900099 | $137,588 | $137,588 |
Miscellaneous Revenue MiscellaneousRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $207,387 | TotalRevenueColumnAmt |
| Exclusion | $207,387 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $8,283,714 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $88,891,678 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $625,697 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $228,355 | UnrelatedBusinessRevenueAmt |
| Exclusion | $8,700,842 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,900,745 | TotalAmt |
| Program Services | $1,900,745 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $512,748 | TotalAmt |
| Program Services | $512,748 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,270,696 | TotalAmt |
| Program Services | $873,582 | ProgramServicesAmt |
| Management And General | $2,397,114 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $35,488,373 | TotalAmt |
| Program Services | $23,593,456 | ProgramServicesAmt |
| Management And General | $11,415,396 | ManagementAndGeneralAmt |
| Fundraising | $479,521 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,945,386 | TotalAmt |
| Program Services | $1,968,643 | ProgramServicesAmt |
| Management And General | $939,588 | ManagementAndGeneralAmt |
| Fundraising | $37,155 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,956,520 | TotalAmt |
| Program Services | $2,644,467 | ProgramServicesAmt |
| Management And General | $1,262,143 | ManagementAndGeneralAmt |
| Fundraising | $49,910 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,320,531 | TotalAmt |
| Program Services | $1,551,001 | ProgramServicesAmt |
| Management And General | $740,257 | ManagementAndGeneralAmt |
| Fundraising | $29,273 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,556,708 | TotalAmt |
| Program Services | $85,382 | ProgramServicesAmt |
| Management And General | $1,471,326 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $128,809 | TotalAmt |
| Management And General | $128,809 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $96,000 | TotalAmt |
| Management And General | $96,000 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,276,977 | TotalAmt |
| Program Services | $2,962,202 | ProgramServicesAmt |
| Management And General | $1,304,562 | ManagementAndGeneralAmt |
| Fundraising | $10,213 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $981,123 | TotalAmt |
| Program Services | $4,694 | ProgramServicesAmt |
| Management And General | $851,686 | ManagementAndGeneralAmt |
| Fundraising | $124,743 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $196,114 | TotalAmt |
| Program Services | $33,411 | ProgramServicesAmt |
| Management And General | $162,590 | ManagementAndGeneralAmt |
| Fundraising | $113 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $376,019 | TotalAmt |
| Program Services | $153,140 | ProgramServicesAmt |
| Management And General | $197,754 | ManagementAndGeneralAmt |
| Fundraising | $25,125 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $371 | TotalAmt |
| Management And General | $371 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,537,460 | TotalAmt |
| Program Services | $1,977,941 | ProgramServicesAmt |
| Management And General | $559,361 | ManagementAndGeneralAmt |
| Fundraising | $158 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $219,340 | TotalAmt |
| Program Services | $123,562 | ProgramServicesAmt |
| Management And General | $80,134 | ManagementAndGeneralAmt |
| Fundraising | $15,644 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $80,578 | TotalAmt |
| Program Services | $44,778 | ProgramServicesAmt |
| Management And General | $35,800 | ManagementAndGeneralAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,726,165 | TotalAmt |
| Program Services | $6,699,249 | ProgramServicesAmt |
| Management And General | $2,026,916 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,763,681 | TotalAmt |
| Program Services | $10,030,415 | ProgramServicesAmt |
| Management And General | $1,733,266 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $630,655 | TotalAmt |
| Program Services | $314,944 | ProgramServicesAmt |
| Management And General | $315,711 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Management And GeneralManagementAndGeneralAmt | Program ServicesProgramServicesAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| FED / STATE INCOME TAX | $44,223 | $44,223 | ||
| LAB SUPPLIES & SERVICES | $5,029,175 | $5,029,175 | ||
| EQUIPMENT & SOFTWARE | $4,015,146 | $1,734,692 | $2,279,055 | $1,399 |
| OTHER SCIENTIFIC | $982,042 | $982,042 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,394,185 | TotalAmt |
| Program Services | $1,076,513 | ProgramServicesAmt |
| Management And General | $1,308,506 | ManagementAndGeneralAmt |
| Fundraising | $9,166 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $94,429,770 | TotalAmt |
| Program Services | $64,841,145 | ProgramServicesAmt |
| Management And General | $28,806,205 | ManagementAndGeneralAmt |
| Fundraising | $782,420 | FundraisingAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,389,037 | BOYAmt |
| EOY | $963,154 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,035,192 | BOYAmt |
| EOY | $4,442,322 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,713,866 | BOYAmt |
| EOY | $3,727,182 | EOYAmt |
Oth Notes Loans Receivable Net OthNotesLoansReceivableNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,565,997 | BOYAmt |
| EOY | $1,493,561 | EOYAmt |
Inventories For Sale Or Use InventoriesForSaleOrUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $261,785 | BOYAmt |
| EOY | $689,899 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,722,950 | BOYAmt |
| EOY | $1,988,548 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $301,703,323 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $131,229,621 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $178,838,822 | BOYAmt |
| EOY | $170,473,702 | EOYAmt |
Investments Other Securities InvestmentsOtherSecuritiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,450,853 | BOYAmt |
| EOY | $6,250,777 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $71,320,000 | BOYAmt |
| EOY | $99,600,000 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $274,298,502 | BOYAmt |
| EOY | $289,629,145 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $90,870,304 | BOYAmt |
| EOY | $113,769,230 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,282,648 | BOYAmt |
| EOY | $3,488,051 | EOYAmt |
Tax Exempt Bond Liabilities TaxExemptBondLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $219,744,537 | BOYAmt |
| EOY | $219,755,485 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $91,688,848 | BOYAmt |
| EOY | $116,481,853 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $405,586,337 | BOYAmt |
| EOY | $453,494,619 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -$137,956,356 | BOYAmt |
| EOY | -$169,411,355 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,668,521 | BOYAmt |
| EOY | $5,545,881 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | -$131,287,835 | BOYAmt |
| EOY | -$163,865,474 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $274,298,502 | BOYAmt |
| EOY | $289,629,145 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$5,538,092 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $51,845 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$27,091,392 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Medical Research Organization | Yes (X) | MedicalResearchOrganizationInd |
Hospital Name And Address HospitalNameAndAddressGrp
Supported Organization Name SupportedOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | SPECTRUM HEALTH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| City | GRAND RAPIDS | CityNm |
| State Abbreviation | MI | StateAbbreviationCd |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $96,000 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $96,000 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $94,333,770 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $94,429,770 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $96,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $96,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $96,000 | CurrentYearMinus1Amt |
| Current Year | $96,000 | CurrentYearAmt |
| Total | $384,000 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $723,759 | BeginningYearBalanceAmt |
| Contributions | $15,000 | ContributionsAmt |
| Investment Earnings Or Losses | $51,845 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $177 | OtherExpendituresAmt |
| End Year Balance | $790,427 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $626,264 | BeginningYearBalanceAmt |
| Contributions | $45,000 | ContributionsAmt |
| Investment Earnings Or Losses | $54,479 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $1,984 | OtherExpendituresAmt |
| End Year Balance | $723,759 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $666,302 | BeginningYearBalanceAmt |
| Contributions | $10,100 | ContributionsAmt |
| Investment Earnings Or Losses | $12,604 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $62,742 | OtherExpendituresAmt |
| End Year Balance | $626,264 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $612,777 | BeginningYearBalanceAmt |
| Investment Earnings Or Losses | $61,326 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $7,801 | OtherExpendituresAmt |
| End Year Balance | $666,302 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributions | $596,343 | ContributionsAmt |
| Investment Earnings Or Losses | $18,408 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $1,974 | OtherExpendituresAmt |
| End Year Balance | $612,777 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Prmnnt Endowment Balance EOY | 1.00000 | PrmnntEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | Yes (1) | EndowmentsHeldRelatedOrgInd |
| Related Org List Sch R | Yes (1) | RelatedOrgListSchRInd |
Land LandGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,288,315 | OtherCostOrOtherBasisAmt |
| Book Value | $5,288,315 | BookValueAmt |
Buildings BuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $230,031,218 | OtherCostOrOtherBasisAmt |
| Depreciation | $79,080,268 | DepreciationAmt |
| Book Value | $150,950,950 | BookValueAmt |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $101,150 | OtherCostOrOtherBasisAmt |
| Depreciation | $101,150 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $63,475,432 | OtherCostOrOtherBasisAmt |
| Depreciation | $51,952,294 | DepreciationAmt |
| Book Value | $11,523,138 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $2,807,208 | OtherCostOrOtherBasisAmt |
| Depreciation | $95,909 | DepreciationAmt |
| Book Value | $2,711,299 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $170,473,702 | TotalBookValueLandBuildingsAmt |
Other Assets Org OtherAssetsOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | PLEDGED SECURITIES | Desc |
| Book Value | $99,600,000 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Other Assets | $99,600,000 | TotalBookValueOtherAssetsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | UNREALIZED LOSS ON INTEREST RATE SWAP | Desc |
| Amt | $116,481,853 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $116,481,853 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $81,110,900 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $51,845 | NetUnrealizedGainsInvstAmt |
| Other Revenue | -$99,642 | OtherRevenueAmt |
| Revenue Not Reported | -$47,797 | RevenueNotReportedAmt |
| Revenue Subtotal | $81,158,697 | RevenueSubtotalAmt |
| Other Revenues Not Included | $7,732,981 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $7,732,981 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $88,891,678 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $113,688,539 | TotExpnsEtcAuditedFinclStmtAmt |
| Other Expenses Included | $26,991,750 | OtherExpensesIncludedAmt |
| Expenses Not Reported | $26,991,750 | ExpensesNotReportedAmt |
| Expenses Subtotal | $86,696,789 | ExpensesSubtotalAmt |
| Other Expenses Not Included | $7,732,981 | OtherExpensesNotIncludedAmt |
| Expenses Not Rpt Fincl Stmt | $7,732,981 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $94,429,770 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART X, LINE 2: | PART X, LINE 1(1) AND LINE 2: THERE ARE NO UNCERTAIN TAX POSITIONS RELATED TO VARI. |
| PART XI, LINE 2D - OTHER ADJUSTMENTS: | RENTAL EXPENSES 109,961. FUNDRAISING EVENT EXPENSE 56,986. ROYALTIES PAYOUT -371. ADDITIONAL IMPAIRMENT -266,743. GAMING EXPENSE 525. |
| PART XI, LINE 4B - OTHER ADJUSTMENTS: | NET ALLOCATED 7,725,025. BAD DEBT ADJUSTMENT 7,956. |
| PART XII, LINE 2D - OTHER ADJUSTMENTS: | RENTAL EXPENSES 109,961. FUNDRAISING EVENT EXPENSE 56,986. LOSS ON INTEREST RATE SWAP 27,091,392. ROYALTIES PAYOUT -371. ADDITIONAL IMPAIRMENT -266,743. GAMING EXPENSE 525. |
| PART XII, LINE 4B - OTHER ADJUSTMENTS: | NET ALLOCATED 7,725,025. BAD DEBT ADJUSTMENT 7,956. |
| PART V | VAN ANDEL INSTITUTE (A RELATED ORGANIZATION) MAINTAINS ENDOWED FUNDS FOR THE BENEFIT OF BOTH VARI AND VAN ANDEL EDUCATION INSTITUTE (A RELATED ORGANIZATION) TO FUND OPERATING EXPENSES. |
| PART XI AND XII, LINE 4B | EXPENSE ALLOCATIONS PRESENTED WITHIN REVENUE. |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (3 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE | 0 | 0 | PROGRAM SERVICES | RESEARCH COLLABORATION - RESEARCH SERVICES, GUEST SPEAKING | $136,402 |
| EUROPE | 0 | 0 | FUNDRAISING | $3,550 | |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | GUEST SPEAKING | $5,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $144,952 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $144,952 | TotalSpentAmt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | GRANT FUNDS ARE MONITORED BY QUARTERLY EXPENDITURE REPORTS BEFORE DISBURSING INCREMENTAL FUNDING. PROGRESS REPORTS ARE REQUIRED ANNUALLY AND REVIEWED BY VAN ANDEL RESEARCH INSTITUTE AND A THIRD PARTY. |
| PART III ACCOUNTING METHOD: |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | SOUTHSIDE | Event1Nm |
| Gross Receipts Event1 | $51,753 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $50,376 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $1,377 | GrossRevenueEvent1Amt |
| Other Direct Expenses Event1 | $16,038 | OtherDirectExpensesEvent1Amt |
| Event2 | NYC MARATHON | Event2Nm |
| Gross Receipts Event2 | $16,559 | GrossReceiptsEvent2Amt |
| Charitable Contri Event2 | $16,559 | CharitableContriEvent2Amt |
| Other Direct Expenses Event2 | $17,727 | OtherDirectExpensesEvent2Amt |
| Other Events Total | 2 | OtherEventsTotalCnt |
| Gross Receipts Other Events | $22,604 | GrossReceiptsOtherEventsAmt |
| Charitable Contri Other Events | $20,689 | CharitableContriOtherEventsAmt |
| Gross Revenue Other Events | $1,915 | GrossRevenueOtherEventsAmt |
| Oth Direct Expnss Other Events | $8,712 | OthDirectExpnssOtherEventsAmt |
| Gross Receipts Total | $90,916 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $87,624 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $3,292 | GrossRevenueTotalEventsAmt |
| Oth Direct Expnss Total Events | $42,477 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $42,477 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | -$39,185 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| MICHIGAN STATE UNIVERSITY | |||||||
| 535 CHESTNUT ROAD ROOM 300 | EAST LANSING | MI | 48824 | 386005984 | 501C3 | $5,245 | SUPPORT FOR TRANSLATIONAL NEUROSCIENCE FUND |
| STAND UP TO CANCER | |||||||
| 10880 WILSHIRE BLVD SUITE 1400 | LOS ANGELES | CA | 90024 | 951644609 | 501C3 | $1,875,000 | RESEARCH COLLABORATION |
| FRIENDS OF CRESCENT PARK | |||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 49503 | 264562012 | 501C3 | $20,500 | SUPPORT MAINTENANCE OF CRESCENT PARK |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 3 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp (5 entries)
| Grant TypeGrantTypeTxt | RecipientRecipientCnt | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Non Cash AssistanceNonCashAssistanceDesc |
|---|---|---|---|---|
| GRADUATE STUDENT STIPENDS FOR MICHIGAN STATE UNIVERSITY STUDENTS | 1 | $46,638 | ||
| GRADUATE STUDENT STIPENDS VAN ANDEL INSTITUTE GRADUATE SCHOOL | 9 | $100,650 | ||
| FOREIGN NATIONAL STIPENDS | 3 | $71,000 | ||
| GUEST WORKER STIPENDS | 6 | $72,377 | ||
| VAN ANDEL INSTITUTE GRADUATE SCHOOL STUDENT TUITION AND FEES REMISSION | 31 | $222,083 | TUITION REMISSION. |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | STUDENTS RECEIVE A STIPEND FOR LIVING EXPENSE AND INSURANCE. GRANT FUNDS TO INSTITUTIONS ARE MONITORED BY QUARTERLY EXPENDITURE REPORTS BEFORE DISBURSING INCREMENTAL FUNDING. PROGRESS REPORTS ARE REQUIRED ANNUALLY AND REVIEWED BY VAN ANDEL RESEARCH INSTITUTE AND A THIRD PARTY. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| First Class Or Charter Travel | Yes (X) | FirstClassOrCharterTravelInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | Yes (1) | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (11 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAVID VAN ANDEL | ||||||||||||||
| CHAIRMAN / CEO | $401,538 | $0 | $97,500 | $0 | $21,218 | $0 | $155,750 | $0 | $1,096 | $0 | $677,102 | $0 | $97,500 | $0 |
| DR JANA HALL | ||||||||||||||
| CHIEF OPERATIONS OFFICER | $388,026 | $0 | $72,109 | $0 | $3,574 | $0 | $134,549 | $0 | $10,840 | $0 | $609,098 | $0 | $72,109 | $0 |
| TIMOTHY MYERS | ||||||||||||||
| V.P. & CHIEF FINANCIAL OFFICER | $296,026 | $0 | $46,929 | $0 | $1,242 | $0 | $88,750 | $0 | $10,840 | $0 | $443,787 | $0 | $46,929 | $0 |
| DR PETER JONES | ||||||||||||||
| CHIEF SCIENTIFIC OFFICER & RES. DIR. | $598,247 | $0 | $130,332 | $0 | $23,954 | $0 | $224,888 | $0 | $10,840 | $0 | $988,261 | $0 | $130,332 | $0 |
| THOMAS CURRAN JR | ||||||||||||||
| GENERAL COUNSEL | $256,604 | $0 | $17,672 | $0 | $2,467 | $0 | $69,757 | $0 | $10,840 | $0 | $357,340 | $0 | $0 | $0 |
| GERALD CALLAHAN | ||||||||||||||
| CHIEF STRATEGIC OFFICER | $312,589 | $0 | $48,907 | $0 | $20,242 | $0 | $114,752 | $0 | $10,840 | $0 | $507,330 | $0 | $0 | $0 |
| KATHY VOGELSANG | ||||||||||||||
| CHIEF INVESTMENT OFFICER | $471,142 | $0 | $249,830 | $0 | $21,322 | $0 | $428,000 | $0 | $10,840 | $0 | $1,181,134 | $0 | $249,830 | $0 |
| DR PATRIK BRUNDIN | ||||||||||||||
| ASSOCIATE RESEARCH DIRECTOR | $478,481 | $0 | $48,967 | $0 | $2,322 | $0 | $106,535 | $0 | $10,840 | $0 | $647,145 | $0 | $48,967 | $0 |
| DR PETER LAIRD | ||||||||||||||
| DISTINGUISHED INVESTIGATOR | $412,004 | $0 | $16,407 | $0 | $3,564 | $0 | $63,792 | $0 | $10,840 | $0 | $506,607 | $0 | $16,407 | $0 |
| TED HEILMAN | ||||||||||||||
| ASSOC DIRECT-SR. PORTFOLIO MGR. | $254,219 | $0 | $142,760 | $0 | $21,322 | $0 | $252,154 | $0 | $10,840 | $0 | $681,295 | $0 | $142,760 | $0 |
| DR GERD PFEIFER | ||||||||||||||
| SR. SCIENTIFIC INVESTIGATOR | $371,239 | $0 | $10,124 | $0 | $3,564 | $0 | $36,763 | $0 | $10,840 | $0 | $432,530 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | VARI ALLOWS FOR FIRST-CLASS OR CHARTER TRAVEL FOR OFFICERS AND TRUSTEES. |
| PART I, LINE 5 | BONUS IS PAID BASED ON VARIABLE PAY PROGRAM OBJECTIVES FOR ELIGIBLE PROGRAM PARTICIPANTS. |
Schedule K IRS990ScheduleK
Tax Exempt Bonds Issues TaxExemptBondsIssuesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
Issuer Name IssuerName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MICHIGAN STRATEGIC FUND | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Issuer EIN | 521417332 | BondIssuerEIN |
| CUSIP | 000000000 | CUSIPNum |
| Bond Issued | 2018-10-01 | BondIssuedDt |
| Issue Price | $220,000,000 | IssuePriceAmt |
| Purpose | REFUND BOND ISSUE 4/01/13 | PurposeDesc |
| Defeased | 0 | DefeasedInd |
| On Behalf Of Issuer | 0 | OnBehalfOfIssuerInd |
| Pool Financing | 0 | PoolFinancingInd |
Tax Exempt Bonds Proceeds TaxExemptBondsProceedsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Total Proceeds | $220,000,000 | TotalProceedsAmt |
| Other Spent Proceeds | $220,000,000 | OtherSpentProceedsAmt |
| Refunding Tax Exempt Bonds | Yes (1) | RefundingTaxExemptBondsInd |
| Refunding Taxable Bonds | 0 | RefundingTaxableBondsInd |
| Final Allocation Made | Yes (1) | FinalAllocationMadeInd |
| Adequate Books And Rec Maint | Yes (1) | AdequateBooksAndRecMaintInd |
Tax Exempt Bonds Private Bus Use TaxExemptBondsPrivateBusUseGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Owning Bond Financed Property | 0 | OwningBondFinancedPropertyInd |
| Any Lease Arrangements | Yes (1) | AnyLeaseArrangementsInd |
| Mgmt Contract Bond Fincd Prop | Yes (1) | MgmtContractBondFincdPropInd |
| Engage Bond Counsel Contracts | Yes (1) | EngageBondCounselContractsInd |
| Any Research Agreements | Yes (1) | AnyResearchAgreementsInd |
| Engage Bond Counsel Research | Yes (1) | EngageBondCounselResearchInd |
| Private Bus Concerning UBI | 0.00210 | PrivateBusConcerningUBIPct |
| Total Private Business Use | 0.00210 | TotalPrivateBusinessUsePct |
| Bond Iss Meet Prvt Sec Pymt Test | 0 | BondIssMeetPrvtSecPymtTestInd |
| Change In Use Bond Financed Prop | Yes (1) | ChangeInUseBondFinancedPropInd |
| Change In Use Bond Financed Prop | 0.00560 | ChangeInUseBondFinancedPropPct |
| Remedial Action Taken | 0 | RemedialActionTakenInd |
| Procs Nonqualified Bond Remdtd | Yes (1) | ProcsNonqualifiedBondRemdtdInd |
Tax Exempt Bonds Arbitrage TaxExemptBondsArbitrageGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Form8038 T Filed | 0 | Form8038TFiledInd |
| Rebate Not Due Yet | 0 | RebateNotDueYetInd |
| Exception To Rebate | 0 | ExceptionToRebateInd |
| No Rebate Due | Yes (1) | NoRebateDueInd |
| Variable Rate Issue | Yes (1) | VariableRateIssueInd |
| Hedge Identified In Bks And Rec | 0 | HedgeIdentifiedInBksAndRecInd |
| Gross Proceeds Invested In GIC | 0 | GrossProceedsInvestedInGICInd |
| Gross Proceeds Invested | 0 | GrossProceedsInvestedInd |
| Written Proc To Monitor Reqs | Yes (1) | WrittenProcToMonitorReqsInd |
Procedures Corrective Action ProceduresCorrectiveActionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Bond Reference | A | BondReferenceCd |
| Procedures Corrective Action | Yes (1) | ProceduresCorrectiveActionInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| DATE REBATE COMPUTATION PERFORMED | ISSUER NAME: MICHIGAN STRATEGIC FUND DATE THE REBATE COMPUTATION WAS PERFORMED: 10/01/2018 |
| PAGE 2 PART III LINE 8C | NO REMEDIAL ACTION WAS REQUIRED BECAUSE NO BONDS BECAME UNQUALIFIED DUE TO THE DISPOSITION. |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (14 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 2 | VARI, VAI, VAEI, AND VAIGS SHARE COMMON MANAGEMENT. DAVID VAN ANDEL, DR. JANA HALL AND TIMOTHY MYERS ARE ALSO OFFICERS OF VAI, AND DAVID VAN ANDEL AND TIMOTHY MYERS ARE OFFICERS OF VAEI AND VAIGS. THOMAS CURRAN JR. IS ALSO AN OFFICER OF VAIGS. GERALD CALLAHAN AND THOMAS CURRAN JR. ARE KEY EMPLOYEES OF VAI AND VAEI. |
| FORM 990, PART VI, SECTION A, LINE 2 | BUSINESS RELATIONSHIP: DAVID VAN ANDEL, GERALD CALLAHAN |
| FORM 990, PART VI, SECTION A, LINE 7A | THE TRUSTEES OF VAN ANDEL INSTITUTE HAVE THE AUTHORITY TO ELECT ONE OR MORE MEMBERS OF VARI'S GOVERNING BODY. |
| FORM 990, PART VI, SECTION B, LINE 11B | FOLLOWING COMPLETION OF THE FINANCIAL STATEMENT AUDIT, THE FORM 990 IS PREPARED AND REVIEWED BY MANAGEMENT. IT IS THEN CIRCULATED TO THE FULL BOARD FOR REVIEW AND COMMENTS PRIOR TO FILING WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | VARI HAS WRITTEN CONFLICT OF INTEREST ("COI") POLICIES AND PROCEDURES WHICH ADMINISTER AND ENFORCE A PROCESS TO IDENTIFY, EVALUATE, AND MANAGE POTENTIAL CONFLICTS OF INTEREST. THESE POLICIES HAVE BEEN APPROVED BY THE BOARD OF TRUSTEES. VAI ADMINISTERS COI POLICIES AND PROCEDURES THROUGH TWO STANDING COMMITTEES: THE CONFLICTS COMMITTEE ("CC") AND THE INSTITUTIONAL COI COMMITTEE ("ICOIC"). COI POLICIES AND PROCEDURES APPLY TO AND SERVE AS A GUIDE FOR EVERYONE IN THE ORGANIZATION. IN PARTICULAR, THEY PROVIDE A USEFUL RESOURCE FOR DEVELOPING ACTIVITIES OR RELATIONSHIPS WITH OUTSIDE ENTITIES OR PERSONS, AND ESTABLISH A PROCESS FOR COMMITTEES TO REVIEW AND MANAGE POTENTIAL CONFLICTS OF INTEREST AS THEY MAY ARISE. THE CC AND ICOIC ARE CHAIRED BY THE GENERAL COUNSEL. THE CC REQUIRES ANNUAL AND UPDATED DISCLOSURES BY COVERED PERSONS AND REVIEWS AND APPROVES MANAGEMENT PLANS. ICOIC POLICIES AND PROCEDURES SERVE AS A GUIDE FOR BOARDS OF TRUSTEES AND SENIOR EXECUTIVES. IN THE EVENT A POTENTIAL COI ARISES AT THE BOARD OR SENIOR EXECUTIVE LEVEL, THE ICOIC MEETS TO REVIEW AND DETERMINE HOW TO MANAGE SUCH A POTENTIAL CONFLICT OF INTEREST IN ACCORDANCE WITH THE COI POLICIES AND PROCEDURES. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPARABILITY DATA FROM AN EXPERT THIRD PARTY IS OBTAINED AND REVIEWED BY THE INDEPENDENT, JOINT COMPENSATION COMMITTEE OF VAN ANDEL RESEARCH INSTITUTE AND RELATED ORGANIZATIONS TO DETERMINE APPROPRIATE COMPENSATION FOR THE CEO, EXECUTIVE MANAGEMENT OFFICIALS, OFFICERS, AND KEY EMPLOYEES, ON BEHALF OF VAN ANDEL RESEARCH INSTITUTE. |
| FORM 990, PART VI, SECTION C, LINE 19 | ALL DOCUMENTS REQUIRED TO BE MADE AVAILABLE TO THE PUBLIC ARE AVAILABLE FOR PUBLIC INSPECTION UPON WRITTEN REQUEST. |
| FORM 990, PART XI, LINE 9: | LOSS ON INTEREST RATE SWAP -27,091,392. |
| FORM 990, PART III, LINE 2 | VAN ANDEL RESEARCH INSTITUTE (VARI) IS DEDICATED TO DETERMINING THE EPIGENETIC, GENETIC, MOLECULAR, AND CELLULAR ORIGINS OF CANCER, PARKINSON'S DISEASE, METABOLIC DISORDERS, AND OTHER ILLNESSES AND TO TRANSLATING THOSE FINDINGS INTO EFFECTIVE THERAPIES. THE INSTITUTE'S SCIENTISTS WORK IN ON-SITE LABORATORIES AND PARTICIPATE IN COLLABORATIONS THAT SPAN THE GLOBE. WITH EPIGENETICS AS ITS COMMON THREAD, THE INSTITUTE IS ORGANIZED INTO THE CENTER FOR CANCER AND CELL BIOLOGY, THE CENTER FOR EPIGENETICS, AND THE CENTER FOR NEURODEGENERATIVE SCIENCE. THE INSTITUTE'S LABS ARE SUPPORTED BY AN OUTSTANDING CORE TECHNOLOGIES AND SERVICES GROUP, WHICH PROVIDES A VIVARIUM, A BIOREPOSITORY, AND VALUABLE ON-SITE CAPABILITIES IN BIOINFORMATICS AND BIOSTATISTICS, CRYO-ELECTRON MICROSCOPY, FLOW CYTOMETRY, IMAGING, GENOMICS, METABOLOMICS AND BIOENERGETICS, PATHOLOGY, AND TRANSGENICS. VARI SCIENTISTS PUBLISHED 136 ARTICLES IN THIS FISCAL YEAR IN PEER-REVIEWED JOURNALS THAT INCLUDED NATURE, CELL, CELL REPORTS, ELIFE, NATURE COMMUNICATIONS, NATURE STRUCTURAL AND MOLECULAR BIOLOGY, CELL METABOLISM, NEUROLOGY, CELL STEM CELL, CANCER CELL, CANCER RESEARCH, MOVEMENT DISORDERS, CHEMICAL SCIENCE, MOLECULAR CELL, CIRCULATION RESEARCH, NATURE NEUROSCIENCE, LANCET NEUROLOGY, ISCIENCE, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES U.S.A., ONCOGENE, CLINICAL CANCER RESEARCH, NEURO-ONCOLOGY, NATURE MATERIALS, BLOOD, EUROPEAN JOURNAL OF NEUROLOGY, CYTOMETRY A, TRENDS IN NEUROSCIENCES, GENOME BIOLOGY, PLOS COMPUTATIONAL BIOLOGY, PLOS GENETICS, JOURNAL OF BIOLOGICAL CHEMISTRY, JOURNAL OF VETERINARY INTERNAL MEDICINE, MOLECULAR CANCER THERAPEUTICS, GENES, NEUROBIOLOGY OF DISEASE, CELL REPORTS MEDICINE, CRISPR JOURNAL, EMBO REPORTS, SCIENTIFIC REPORTS, STRUCTURE, FASEB JOURNAL, CALCIFIED TISSUE INTERNATIONAL, EPIGENETICS AND CHROMATIN, JOURNAL OF MOLECULAR BIOLOGY, JOURNAL OF PARKINSON'S DISEASE, BIOCHEMICAL JOURNAL, JOURNAL OF CLINICAL MEDICINE, BIOANALYSIS, AND JOURNAL OF CHEMICAL PHYSICS. |
| FORM 990, PART III, LINE 4A | LINE 4A - PROGRAM SERVICE ACTIVITY #1 CENTER FOR CANCER AND CELL BIOLOGY THE CENTER FOR CANCER AND CELL BIOLOGY, DIRECTED BY BART WILLIAMS, PH.D., COMPRISES 14 LABORATORIES ENGAGED IN BASIC RESEARCH IN MOLECULAR AND STRUCTURAL BIOLOGY AND IN TRANSLATIONAL RESEARCH ON CANCER, SKELETAL DISEASES, AND METABOLISM AND NUTRITION. THE CENTER IS DIVIDED INTO PROGRAMS IN STRUCTURAL BIOLOGY; SKELETAL DISEASE AND CANCER THERAPEUTICS; AND METABOLIC AND NUTRITIONAL PROGRAMMING. IN THIS FISCAL YEAR, RESEARCHERS AND TRAINEES WITHIN THE CENTER RECEIVED TWO R01 AWARDS, TWO R35 AWARDS, AN R21 AWARD, AND AN F99 FELLOWSHIP FROM THE NATIONAL INSTITUTES OF HEALTH. OTHER NEW GRANTS WERE FROM THE PEW CHARITABLE TRUSTS, THE SLOAN FOUNDATION, AND THE BREAST CANCER RESEARCH FOUNDATION. TWO NON-NIH POSTDOCTORAL FELLOWSHIPS WERE ALSO RECEIVED, FROM THE AMERICAN HEART ASSOCIATION AND THE AMERICAN CANCER SOCIETY. THE WILLIAMS LAB PRODUCED SEVERAL STUDIES ON BONE-RELATED ISSUES. A PROJECT ON GALECTIN-3 UNCOVERED THE MECHANISM FOR SEX-DEPENDENT EFFECTS OF LOSS OF THIS MOLECULE ON AGING BONE. GALECTIN-3 MAY BE A THERAPEUTIC TARGET AGAINST THE LOSS OF SEX HORMONE PRODUCTION SUCH AS OCCURS FOLLOWING MENOPAUSE IN WOMEN OR IN ANDROGEN DEPLETION THERAPY FOR PROSTATE CANCER PATIENTS (MAUPIN ET AL., CALCIFIED TISSUE INTERNATIONAL 106(3): 283-293). ANOTHER STUDY RELATED TO INDIVIDUALS WHO HAVE LOST THE FUNCTION OF THE LRP5 PROTEIN; THEY DEVELOP OSTEOPOROSIS AND DEFECTIVE RETINAL VASCULATURE. THE LAB USED CRISPR-CAS9 TECHNOLOGY TO KNOCK OUT THE LRP5 GENE IN RATS, WHICH PROVIDES A NEW MODEL FOR STUDYING THE ROLE OF WNT SIGNALING IN THE DEVELOPMENT OF BONE AND THE RETINA, AS WELL AS FOR RESEARCH INTO HOW TO TREAT PATIENTS WHO HAVE MUTANT FORMS OF LRP5 (UBELS ET AL., CRISPR JOURNAL 3(4): 284-298). THE LAB ALSO COLLABORATED WITH A JOHNS HOPKINS LABORATORY TO STUDY THE FRIZZLED-4 (FZD4) RECEPTOR PROTEIN. THE DATA SHOWED THAT FZD4 MAY HAVE OVERLAPPING FUNCTIONS WITH FZD8, BUT THAT FZD4 IS REQUIRED FOR NORMAL BONE DEVELOPMENT AND MINERALIZATION (KUSHWAHA ET AL., JOURNAL OF CELL PHYSIOLOGY 235(10): 6673-6683). IN THE STRUCTURAL BIOLOGY PROGRAM, THE LI LAB PUBLISHED THE FIRST CRYOELECTRON MICROSCOPY STRUCTURE OF THE EUKARYOTIC ENDOPLASMIC RETICULUM MEMBRANE COMPLEX, WHICH INSERTS PROTEINS THROUGH A MEMBRANE. PART OF THE STRUCTURE RESEMBLES A PROKARYOTIC INSERTASE ENZYME, SHOWING CONSERVATION OF STRUCTURE THROUGHOUT EVOLUTION AND SUGGESTING THAT THEIR ENZYME MECHANISMS MAY BE SIMILAR (BAI ET AL., NATURE 584(7821): 475-478). ANOTHER PAPER REPORTED A HIGH-RESOLUTION STRUCTURE FOR THE EUKARYOTIC CMG HELICASE. DETAILS OF THE STRUCTURE ALLOWED THE AUTHORS TO DESCRIBE HOW THE HELICASE PULLS THE DNA THROUGH A MOLECULAR TUNNEL, ALLOWING IT TO SEPARATE THE TWO DNA STRANDS FOR REPLICATION (YUAN ET AL., NATURE COMMUNICATIONS 11: 688). A THIRD PROJECT PRODUCED AN ATOMIC STRUCTURE FOR THE POLYMERASE EPSILON ENZYME, WHICH IS A DIMER OF TWO DIFFERENT POL "MODULES". THE SOLVED STRUCTURE SUGGESTS THAT A FOLD IN THE DBP2 SUBUNIT DIRECTS THE DNA LEADING STRAND FROM THE CMG COMPLEX TO THE POL EPISILON ACTIVE SITE (YUAN ET AL., NATURE COMMUNICATIONS 11: 356). THESE LAST TWO PAPERS TOGETHER SHED NEW LIGHT ON THE ATOMIC-LEVEL MECHANISM OF HOW DNA IS REPLICATED IN THE CELL. THE DU AND LU LABS PUBLISHED THREE PAPERS IN THE PRESTIGIOUS JOURNAL NATURE ON THE STRUCTURES OF ION CHANNELS, WHICH ARE PROTEINS THAT ALLOW IONS INTO AND OUT OF CELLS. THEY PUBLISHED STRUCTURES FOR THE HUMAN CALHM2 ION CHANNEL IN AN ACTIVE AND AN INHIBITED STATE. THEY ALSO PROPOSED A GATING MECHANISM FOR CALHM2 IN WHICH THE S1 HELIX COARSELY ADJUSTS, AND THE N-TERMINAL HELIX FINE-TUNES, THE PORE SIZE (CHOI ET AL., NATURE 576(7785): 163-167). PANNEXIN IS A PROTEIN INVOLVED IN BLOOD PRESSURE REGULATION AND OTHER IMPORTANT PROCESSES. THE LABS SOLVED THE STRUCTURES OF HUMAN PANNEXIN 1 (PANX1) IN THREE STATES, AT DOWN TO 2.8-ANGSTROM RESOLUTION. THEY WERE ABLE TO DESCRIBE ITS GATING MECHANISM FOR TWO DIFFERENT ION PATHWAYS, AS WELL AS THE ROLE OF CARBENOXOLONE AS A BLOCKER OF THE PANNEXIN CHANNEL (RUAN ET AL., NATURE 584(7822): 646-651). FINALLY, THEY ALSO STUDIED THE PROTON-ACTIVATED CHLORIDE CHANNEL (PAC), WHICH IS INVOLVED IN TISSUE INJURY. THEIR PAPER DESCRIBED THE CHANGES OF PROTEIN CONFORMATION WITH A CHANGE IN PH IN THE CELLULAR ENVIRONMENT, AND ALSO THE MOLECULAR ASSEMBLY OF THE THREE PAC SUBUNITS. THESE RESULTS PROVIDE A BASIS FOR UNDERSTANDING THE ATOMIC-LEVEL MECHANISMS OF PAC (RUAN ET AL., NATURE 588(7837): 350-354). THE STRUCTURAL LAB OF KARSTEN MELCHER PUBLISHED SEVERAL PAPERS IN COLLABORATION WITH LABS AT VARI AND ELSEWHERE. METHYLTRANSFERASES ARE ENZYMES THAT PLACE METHYL GROUPS ONTO DNA, AN IMPORTANT EPIGENETIC MODIFICATION. THE LABS OF MELCHER AND PETER JONES SOLVED THE STRUCTURES OF TWO SUCH ENZYMES, DNMT3A AND DNMT3B, BOUND TO NUCLEOSOMES. THE STRUCTURES SUGGEST THAT IN ORDER TO ADD THE METHYL GROUP, THE DNA MUST BE MOVED RELATIVE TO THE NUCLEOSOME CORE (XU ET AL., NATURE 586(7827): 151-155). ANOTHER STUDY USED MOLECULAR DYNAMICS SIMULATIONS TO DETERMINE HOW THE DRUG FENTANYL BINDS TO THE MU-OPIOID RECEPTOR. THE RESULTS SUGGEST AN ACTIVATION MECHANISM AND PROVIDE A RATIONAL FRAMEWORK FOR IMPROVING THE SAFETY PROFILES OF FENTANYL-BASED ANALGESICS (DE WAAL ET AL., PLOS COMPUTATIONAL BIOLOGY 16(4): E1007394). THE MELCHER LAB ALSO STUDIED TWO G-PROTEIN-COUPLED RECEPTORS (GPCRS) CALLED CFR1R AND CFR2R, WHICH ARE ACTIVATED BY ENDOCRINE HORMONES AND ARE INVOLVED IN THE BODY'S STRESS RESPONSES. THE PEPTIDE-BINDING AMINO ACIDS IN THESE TWO RECEPTORS DIFFER FROM THOSE IN OTHER CLASS B GPCRS, AND BOTH STRUCTURES HAD BOUND CHOLESTEROL MOLECULES. THIS WORK PROVIDES A MODEL FOR STUDYING THE MEMBRANE PROTEIN-LIPID INTERACTIONS OF CLASS B GPCRS (MA ET AL., MOLECULAR CELL 77(3): 669-680.E4). FINALLY, THEY STUDIED THE CANNABINOID RECEPTOR CB2 AS A TARGET FOR TREATING NEURODEGENERATIVE DISORDERS AND FOR TREATING PAIN WITH FEWER SIDE EFFECTS. THE STRUCTURE OF THE HUMAN CB2-G(I) SIGNALING COMPLEX WAS SOLVED WITH A BOUND AGONIST, SHOWING THE BINDING MODE AND HOW CB2 DISTINGUISHES AGONISTS FROM ANTAGONISTS. THIS KNOWLEDGE SHOULD AID IN DEVELOPING MORE-EFFECTIVE DRUGS THAT TARGET THE CANNABINOID SYSTEM (XING ET AL., CELL 180(4): 645-654.E13). IN THE METABOLISM PROGRAM, THE RUSSELL JONES LAB INVESTIGATED THE METABOLIC ADAPTATION OF CANCER CELLS THROUGH THE LIVER KINASE B1-AMPK PATHWAY. THE MICRORNA MIR-17 SENSITIZED LYMPHOMA CELLS TO TREATMENT WITH BIGUANIDES, WHICH STRESS THE CELLS BY INHIBITING THE KREBS CYCLE AND MITOCHONDRIAL RESPIRATION. MIR-17 EXPRESSION MAY BE A BIOMARKER FOR BIGUANIDE SENSITIVITY IN CANCERS (IZREIG ET AL., CELL REPORTS MEDICINE 1(2): 100014). THE LAB ALSO INVESTIGATED THE REASONS FOR AND EFFECTS OF HIGH SERUM ACETATE AT SITES OF INFECTION. THEY FOUND THAT AN ABUNDANCE OF ACETATE IMPROVED PATHOGEN CLEARANCE WHILE REDUCING IMMUNOPATHOLOGY. OVERALL, THE WORK SHOWED THAT AT DIFFERENT STAGES OF THE IMMUNE RESPONSE, ACETATE HAS DISTINCTLY DIFFERENT EFFECTS WITHIN THE SAME CELL TYPE (BALMER ET AL., CELL METABOLISM 32(3): 457-467.E5). A THIRD PAPER REPORTED THE EFFECTS OF METHOTREXATE ON CELLULAR METABOLISM, ONE OF WHICH WAS AMPK ACTIVATION. THAT ACTIVATION WAS NECESSARY FOR BOTH THE ANTI-PROLIFERATIVE AND PRO-RESPIRATORY EFFECTS OF METHOTREXATE. COMBINING METHOTREXATE WITH THE AMPK ACTIVATOR PHENFORMIN POTENTIATES THE ANTI-PROLIFERATIVE ACTIVITY IN CANCER CELLS (PAPADOPOLI ET AL., SCIENTIFIC REPORTS 10(1): 7838). THE JONES AND KRAWCZYK LABS COLLABORATED IN A STUDY OF MICRORNA-9 IN THE DENDRITIC CELLS OF THE INNATE IMMUNE SYSTEM. THE RESULTS SHOWED THAT MIR-9 AIDED THE TRANSITION OF DENDRITIC CELLS FROM STEADY STATE TO A MATURE STATE BY AFFECTING THE EXPRESSION OF SEVERAL NEGATIVE REGULATORS OF CELL TRANSCRIPTION, INCLUDING POLYCOMB GROUP FACTOR 6 (CORDEIRO ET AL., CELL REPORTS 21(5): 107585). METHIONINE IS A KEY NUTRIENT AFFECTING EPIGENETIC REPROGRAMMING IN CD4+ T HELPER (TH) CELLS. A COLLABORATION AMONG THE R. JONES, KRAWCZYK, AND POSPISILIK LABS SHOWED THAT A LACK OF METHIONINE AFFECTED THE PROMOTER REGIONS OF GENES INVOLVED IN THE PROLIFERATION OF INFLAMMATORY TH17 CELLS AND CYTOKINE PRODUCTION. IN A MOUSE MODEL OF MULTIPLE SCLEROSIS, LACK OF DIETARY METHIONINE LED TO REDUCED T CELL-MEDIATED NEUROINFLAMMATION AND DISEASE ONSET. METHIONINE RESTRICTION MAY BE A USEFUL INTERVENTION FOR TREATING AUTOIMMUNE CONDITIONS SUCH AS MS (ROY ET AL., CELL METABOLISM 31(2): 250-266.E9). FINALLY, THE STEENSMA LAB STUDIED KINASE ENZYME INHIBITION IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS USING CAPMATINIB, TRAMETINIB, OR DOXORUBICIN TREATMENT. THEY FOUND BROAD AND REDUNDANT KINOME ADAPTATIONS, SHOWING THAT THESE TUMORS ARE CAPABLE OF PROFOUND SIGNALING PLASTICITY IN THE FACE OF SUCH TREATMENTS. SOME OF THE DATA SUGGEST THAT TARGETING AXL OR MFKB MAY LESSEN THE RESISTANCE TO THESE THERAPIES (GRIT ET AL., GENES 11(3): 331). |
| FORM 990, PART III, LINE 4B | LINE 4B - PROGRAM SERVICE ACTIVITY #2 CENTER FOR EPIGENETICS THE CENTER, ESTABLISHED IN 2014 AND NOW DIRECTED BY J. ANDREW POSPISILIK, PH.D., HAS 10 LABORATORIES STUDYING EPIGENETICS, EPIGENOMICS, AND THE ROLE OF EPIGENETIC DYSFUNCTION IN CANCER, NEURODEGENERATIVE DISEASE, CARDIOVASCULAR DISEASE, AND VIRAL TRANSCRIPTION. NEW GRANT AWARDS IN THIS FISCAL YEAR FOR CENTER RESEARCHERS AND TRAINEES INCLUDED AN R01 AND AN R21 FROM THE NATIONAL INSTITUTES OF HEALTH, AS WELL AS AN NIH GRANT SUB-AWARD. THE LAB OF PETER JONES CONDUCTED A STUDY OF THE WHOLE-GENOME SEQUENCES OF 53 ORGANISMS, AND THEY SHOWED A POSITIVE CORRELATION BETWEEN THE SIZE OF A GENOME AND THE PERCENTAGE OF TRANSPOSABLE ELEMENTS (TES) IT CONTAINS. THE METHYLATION OF THE DNA OF SUCH ELEMENTS ALLOWS FOR THEIR LONG-TERM RESIDENCE IN THE GENOME, AND THEIR ACCUMULATION LEADS TO AN INCREASE IN GENOME SIZE. IT ALSO LEADS TO NEW OPPORTUNITIES FOR GENE CONTROL BY TE-BASED REGULATORY SITES (ZHOU ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA 117(32): 19359-19366). ANOTHER PROJECT LOOKED AT THE USE OF DNA METHYLTRANSFERASE INHIBITORS AS DRUGS FOR TREATING HEMATOLOGIC CANCERS. IN RESPONSE TO THIS TREATMENT, MALIGNANT CELLS SHOWED THE ACTIVATION OF NEWER TRANSPOSABLE ELEMENTS OF SEVERAL KINDS, AND CELL CULTURES SHOWED THE ACTIVATION OF SIX GENES IN THE TYPE I IFN PATHWAY. THUS, THE TES ELICITED AN IMMUNE REACTION THAT MAY BE IMPORTANT IN THE PATIENT'S RESPONSE TO THERAPY (OHTANI ET AL., CANCER RESEARCH 80(12): 2441-2450). THE ROTHBART LAB'S RESEARCH INVOLVES THE GAIN AND LOSS OF METHYL GROUPS ADDED TO DNA AND THE FUNCTION OF THOSE CHANGES. THE LIGASE UHRF1 IS KNOWN TO HELP MAINTAIN ABNORMAL DNA METHYLATION IN CANCER CELLS. THE LAB INVESTIGATED THIS ENZYME'S ACTIVITY AND THE PATTERN OF DNA METHYL GROUPS IN A VARIETY OF EXPERIMENTS, WHICH SHOWED THAT UHRF1 SELECTIVELY IDENTIFIES SPECIFIC METHYLATION POSITIONS ON BOTH DNA AND HISTONE PROTEINS. THEY ALSO FOUND THAT THE READER ACTIVITY OF THE UHRF1 TANDEM TUDOR DOMAIN IS DISPENSABLE FOR MAINTAINING DNA METHYLATION IN CANCER CELLS (VAUGHAN ET AL., EPIGENETICS AND CHROMATIN 13: 44). THE LAB HAS DEVELOPED A HIGH-THROUGHPUT BINDING ASSAY TO SHOW THE SEQUENCE DETERMINANTS OF METHYLLYSINE-DRIVEN PROTEIN INTERACTIONS. THEY ALSO USED IT TO IDENTIFY THE BINDING LOCALES OF HISTONE ANTIBODIES AND FOUND THAT ONLY A FEW AMINO ACIDS DRIVE EPITOPE RECOGNITION. THIS ASSAY WILL BE A VALUABLE RESOURCE FOR FUTURE STUDIES OF METHYLLYSINE-DRIVEN PROTEIN INTERACTIONS (KUPAI ET AL., FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY 8: 241). IN A THIRD PAPER, THE LAB DESCRIBED A NEW MODEL DEFINING CHROMATIN IMMUNOPRECIPITATION (CHIP-SEQ) TECHNOLOGY, AND THEY EXPLORED THE MODEL'S IMPLICATIONS FOR THE USE OF EXOGENOUS ADDITIVES (SPIKE-INS) WITH CHIP-SEQ. THEY IDENTIFIED A NEW SENSITIVITY ISSUE THAT LIMITS THE UTILITY AND TRUSTWORTHINESS OF SPIKE-INS. THIS PROMISES TO BE A VALUABLE STEP IN IMPROVING THE WIDELY USED CHIP-SEQ TECHNOLOGY (DICKSON ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY 295(47): 15826-15837). FINALLY, THEY COLLABORATED IN A PROJECT LOOKING AT THE RAPID TRANSCRIPTION OF SELECT GENES IN RESPONSE TO CUES SUCH AS THE SENSING OF PATHOGENS BY MACROPHAGES. THE AUTHORS PROPOSE THAT FEATURES OF THE HISTONE H3.3 PROVIDE PREFERENTIAL ACCESS TO THE TRANSCRIPTIONAL MACHINERY, AND THAT DEDICATED MECHANISMS ENABLE RAPID TRANSCRIPTION INVOLVING H3.3, ITS PHOSPHORYLATION, AND BOTH THE RECRUITMENT AND EJECTION OF CHROMATIN REGULATORS (ARMACHE ET AL., NATURE 583(7818): 852-857). THE SHI LAB TOOK PART IN A STUDY REPORTING THAT WNT ACTIVATION STABILIZES THE EPIGENETIC REGULATOR PROTEIN KDM4C, WHICH PROMOTES TUMORIGENESIS AND AIDS THE SURVIVAL OF HUMAN GLIOBLASTOMA CELLS. WNT-KDM4C-BETA-CATENIN SIGNALING REPRESENTS A NEW MECHANISM FOR THE TRANSCRIPTION OF WNT TARGET GENES AND THE REGULATION OF TUMORIGENESIS, AND IT HAS IMPORTANT CLINICAL IMPLICATIONS FOR THIS CANCER (CHEN ET AL., CANCER RESEARCH 80(5): 1049-1063). A SECOND PAPER LOOKED AT THE HUMAN ENZYME HERC2, WHICH IS LINKED TO NEUROLOGICAL DISEASES AND CANCER. A DETAILED STRUCTURE OF THE ENZYME'S ZZ DOMAIN WAS SOLVED, SHOWING THE NEGATIVELY CHARGED SITE OF THAT DOMAIN HAS A CRUCIAL ROLE IN THE ENZYME'S INTERACTIONS. THE ZZ DOMAIN MAY PLAY A ROLE IN THE ASSOCIATION OF HERC2 WITH CHROMATIN (LIU ET AL., STRUCTURE 28(11): 1225-1330.E3). ANOTHER PAPER FROM THE LAB LOOKED INTO CHANGES FOUND IN AN AGGRESSIVE FORM OF ACUTE MYELOID LEUKEMIA. THE DATA SUPPORT A CRUCIAL ROLE OF THE FUSION PROTEIN NUP98-PHF23 IN DRIVING LEUKEMOGENESIS. THEY HIGHLIGHT A DIRECT CORRELATION BETWEEN LEUKEMIC TRANSFORMATION AND THE ABILITIES OF NUP98-PHD FINGER CHIMERAS TO ASSOCIATE WITH H3K4ME3 METHYLATION SITES ON CHROMATIN (ZHANG ET AL., NATURE COMMUNICATIONS 11: 3339). THESE STUDIES ALL ADD TO OUR KNOWLEDGE OF THE MOLECULAR BASIS OF CANCER. THE LAIRD LAB CONTRIBUTED TO A PHASE 1 TRIAL OF TRC102 IN COMBINATION WITH TEMOZOLOMIDE FOR PATIENTS WHO HAD REFRACTORY SOLID TUMORS. OF 52 PATIENTS, FOUR HAD PARTIAL RESPONSES AND 13 HAD A BEST RESPONSE OF STABLE DISEASE. THE COMBINATION TREATMENT IS ACTIVE, AND THE SIDE-EFFECT PROFILE IS MANAGEABLE (COYNE ET AL., ONCOTARGET 11(44): 3959-3971). ANOTHER PAPER STUDIED TEN ESTIMATION METHODS FOR TUMOR PURITY IN A COHORT OF 333 PROSTATE CANCER PATIENTS. THE DATA SHOWED POOR CONCORDANCE BETWEEN PATHOLOGIC AND MOLECULAR PURITY ESTIMATES. THUS, THE CHOICE OF TUMOR PURITY ESTIMATION METHOD MAY HAVE A PROFOUND IMPACT ON THE INTERPRETATION OF GENOMIC ASSAYS, HIGHLIGHTING A NEED FOR IMPROVED WAYS TO ASSESS TUMOR PURITY (HAIDER ET AL., JCO PRECISION ONCOLOGY 4: 995-1005). THE SHEN LAB TOOK PART IN A PHASE II CLINICAL TRIAL OF METFORMIN AGAINST EPITHELIAL OVARIAN CANCER. METFORMIN WAS WELL TOLERATED, AND TREATED TUMORS SHOWED INCREASED SENSITIVITY TO CISPLATIN EX VIVO. IT ALTERED THE METHYLATION SIGNATURE OF CARCINOMA-ASSOCIATED MESENCHYMAL STEM CELLS, PREVENTING CHEMORESISTANCE IN VITRO. THE STUDY SUPPORTS THE USE OF METFORMIN IN PHASE II STUDIES (BROWN ET AL., JCI INSIGHT 5(11): E1332247). THE SHEN AND TRICHE LABS BOTH CONTRIBUTED TO A STUDY OF UTERINE FIBROIDS. SIGNIFICANT OVERLAP OF DIFFERENTIALLY EXPRESSED GENES WAS OBSERVED FOR CERVICAL STROMA OR UTERINE FIBROIDS COMPARED WITH NORMAL MYOMETRIUM. THESE ANALYSES SHOW A POSSIBLE ROLE OF DNA METHYLATION IN FIBROID BIOLOGY, AND THEY SUGGEST THAT HOMEOTIC TRANSFORMATION OF MYOMETRIAL CELLS TO A MORE CERVICAL STROMA PHENOTYPE COULD BE AN IMPORTANT MECHANISM IN THE DISEASE (GEORGE ET AL., CELL REPORTS 29(12): 4069-4085.E6). STEFAN JOVINGE'S LAB HELPED EVALUATE THE EFFECT OF S100A9 BLOCKADE ON POST-ISCHEMIC CARDIAC REPAIR. SEVEN DAYS OF TREATMENT WERE BENEFICIAL, BUT 21 DAYS OF BLOCKADE LED TO DETERIORATION OF CARDIAC FUNCTION IN MICE. THUS, THERE IS A THERAPEUTIC WINDOW FOR OPTIMAL EFFECT OF THIS TREATMENT IN ACUTE MYOCARDIAL INFARCTION (MARINKOVIC ET AL., CIRCULATION RESEARCH 127(5): 664-676). IN ANOTHER STUDY, THE LAB COLLABORATED IN A STUDY OF THE CO-CULTURE OF CARDIOMYOCYTES AND SYMPATHETIC NEURONS, BOTH DERIVED FROM HUMAN-INDUCED PLURIPOTENT STEM CELLS. THE DATA SHOWED THE DEVELOPMENT OF ELECTROPHYSIOLOGICALLY FUNCTIONAL SYMPATHETIC NEURONS THAT ARE CAPABLE OF MODULATING THE BEATING RATE OF THE CARDIOMYOCYTES IN VITRO. THESE HUMAN CELL CO-CULTURES PROVIDE A NOVEL MULTICELLULAR MODEL FOR THE STUDY OF NEUROCARDIAC MODULATION UNDER PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS (WINBO ET AL., AMERICAN JOURNAL OF PHYSIOLOGY - HEART AND CIRCULATORY PHYSIOLOGY 319(5): H927-H937). THE POSPISILIK LAB COAUTHORED A PAPER SHOWING THAT MACROPHAGES CAN MAINTAIN INSULIN SECRETION IN VIVO FOLLOWING BETA-CELL DEATH, WITH NO EFFECTS ON ISLET CELL TURNOVER. IGF-1 NEUTRALIZATION DURING STREPTOZOTOCIN TREATMENT DECREASED INSULIN SECRETION WITHOUT AFFECTING ISLET CELL APOPTOSIS OR PROLIFERATION. A HIGH-FAT DIET PLUS STZ FURTHER SKEWED ISLET MACROPHAGES TO A REPARATIVE STATE (NACKIEWICZ ET AL., ISCIENCE 23(1): 100775). THE LAB ALSO COLLABORATED IN RESEARCH INTO ADHESION G-PROTEIN-COUPLED RECEPTORS IN ADIPOSE TISSUE. THE PROJECT CONCLUDED THAT ADHESION GPCRS ARE SIGNIFICANTLY INVOLVED IN QUALITATIVE AND QUANTITATIVE LIPID ACCUMULATION IN ADIPOCYTES AND CAN CONTROL LIPOLYSIS. FACTORS DRIVING ADIPOCYTE FORMATION AND FUNCTION ARE GOVERNED BY SIGNALING PATHWAYS INDUCED BY ADHESION GPCRS, SUGGESTING THAT THESE RECEPTORS ARE POTENTIAL TARGETS FOR TREATING OBESITY (SUCHY ET AL., INTERNATIONAL JOURNAL OF OBESITY 44(10): 2124-2136). |
| FORM 990, PART III, LINE 4C | LINE 4C - PROGRAM SERVICE ACTIVITY #3 CENTER FOR NEURODEGENERATIVE SCIENCE THE CENTER WAS ESTABLISHED IN 2012 UNDER DIRECTOR PATRIK BRUNDIN, M.D., PH.D. IN 2020, IT HAD NINE LABORATORIES STUDYING PARKINSON'S DISEASE, ALZHEIMER'S DISEASE, AND THE RELATIONSHIPS BETWEEN DEPRESSION, SUICIDE, AND BRAIN INFLAMMATION. THE NEWEST LABORATORY, THAT OF MICHAEL HENDERSON, PH.D., FOCUSES ON THE PATHOGENESIS AND POTENTIAL THERAPIES FOR PARKINSON'S DISEASE AND DEMENTIA WITH LEWY BODIES. CENTER RESEARCHERS AND TRAINEES DURING THIS FISCAL YEAR RECEIVED FIVE R01S AND AN R21 FROM THE NATIONAL INSTITUTES OF HEALTH, TWO AWARDS FROM THE MICHAEL J. FOX FOUNDATION AND THREE FROM THE ASAP COLLABORATIVE RESEARCH NETWORK, AND A SUBAWARD FROM THE PARKINSON'S FOUNDATION. A POSTDOCTORAL FELLOWSHIP WAS ALSO RECEIVED FROM THE PARKINSON'S FOUNDATION. THE LENA BRUNDIN LAB EXPLORED THE INCREASED INFLAMMATION REPORTED IN MAJOR DEPRESSIVE DISORDER (MDD), WHICH MAY BE DRIVEN BY VITAMIN D DEFICIENCY. WHILE 25(OH)D LEVELS DID NOT SIGNIFICANTLY DIFFER IN MDD VS. CONTROLS, LOWER 25(OH)D WAS ASSOCIATED WITH INDICES OF IMMUNE ACTIVATION IN MDD, ESPECIALLY IN CASES WITH SUICIDAL IDEATION. THE FINDINGS ARE CONSISTENT WITH RELATIVELY LOW 25(OH)D LEVELS IN MDD BEING ASSOCIATED WITH A PRO-INFLAMMATORY STATE (GRUDET ET AL., JOURNAL OF AFFECTIVE DISORDERS 267: 33-41). ANOTHER STUDY FOCUSED ON TRYPTOPHAN (TRP) METABOLITES IN THE CEREBROSPINAL FLUID (CSF), WHICH MAY BE MODULATORS OF PSYCHIATRIC DISEASE. THE LAB SHOWED THE FEASIBILITY OF BIOCHEMICAL ANALYSIS OF CSF TRP METABOLITES, INCLUDING THE SEPARATION OF PICOLINIC ACID FROM NICOTINIC ACID. THEY ALSO CONFIRMED PRIOR FINDINGS OF ABERRANT CSF QUINOLINIC ACID AND PICOLINIC ACID IN SUICIDE ATTEMPTERS (SCHWIELER ET AL., BIOANALYSIS 12(6): 379-392). THE LABS OF PATRIK AND LENA BRUNDIN COLLABORATED IN LOOKING AT TRYPTOPHAN METABOLITES IN PARKINSON'S DISEASE PATIENTS. PD SUBJECTS HAD OVER 100% HIGHER 3-HYDROXYKYNURENINE AND 14% LOWER 3-HYDROXYANTHRANILIC ACID CONCENTRATIONS IN THEIR PLASMA. OVERALL, KYNURENINE PATHWAY METABOLITES WERE ALTERED IN PD PATIENTS IN BOTH THE PERIPHERY AND THE CENTRAL NERVOUS SYSTEM, AND THESE CHANGES ASSOCIATED WITH SYMPTOM SEVERITY (HEILMAN ET AL., MOVEMENT DISORDERS 35(11): 2028-2037). THE PATRIK BRUNDIN LAB EVALUATED THE SMELLING FUNCTION OF MICE AFTER INJECTING ALPHA-SYNUCLEIN PREFORMED FIBRILS INTO THE OLFACTORY BULB. NO OVERT IMPAIRMENTS IN SNIFFING ABILITY WERE EVIDENT. AT ALL TIME POINTS, FEMALES HAD A REDUCED ABILITY TO DETECT ODORS IN A PLETHYSMOGRAPHY TEST. THIS SENSITIVE METHOD COULD BE USED TO DEFINE HOW ALPHA-SYNUCLEIN PATHOLOGY AFFECTS OTHER ASPECTS OF OLFACTORY PERCEPTION AND TO CLARIFY THE NEUROPATHOLOGICAL BASIS OF THESE DEFICITS (JOHNSON ET AL., SCIENTIFIC REPORTS 10(1): 9242). A SECOND SET OF EXPERIMENTS FOUND PATHOLOGY IN BOTH THE OLFACTORY BULB AND THE PIRIFORM CORTEX OF MICE INJECTED WITH ALPHA-SYNUCLEIN FIBRILS. THE MICE DISPLAYED ABERRANTLY HIGH ODOR-EVOKED POWER IN THE BETA SPECTRAL RANGE. NO SIMILAR CHANGE WAS FOUND IN THE PIRIFORM CORTEX, DESPITE HIGH LEVELS OF PATHOLOGY. THESE RESULTS PROVIDE EVIDENCE THAT SYNUCLEINOPATHY AFFECTS NEURAL ACTIVITY IN THE OLFACTORY SYSTEM AT THE NETWORK LEVEL (KULKARNI ET AL., JOURNAL OF PARKINSON'S DISEASE 10(4): 1411-1427). A THIRD PAPER REPORTED THE INJECTION OF FIVE CONFORMATIONAL STRAINS OF ALPHA-SYNUCLEIN INTO THE OLFACTORY BULB OF FEMALE MICE. EACH STRAIN PROPAGATED PATHOLOGY THROUGH THE CENTRAL NERVOUS IN DISTINCT PATTERNS. THE DATA SUPPORT THE VIEW THAT THE CONFORMATIONS OF ALPHA-SYNUCLEIN ASSEMBLIES MAY UNDERLIE DIFFERENT PROPAGATION PATTERNS WITHIN THE HUMAN BRAIN (REY ET AL., ACTA NEUROPATHOLOGICA COMMUNICATIONS 7:221). THE MOORE LAB STUDIED THE LRRK2 KINASE ENZYME AND IDENTIFIED ITS FUNCTION IN REGULATING MEMBRANE FUSION AT THE TRANS-GOLGI NETWORK, INFLUENCING BOTH RETROGRADE AND POST-GOLGI TRAFFICKING PATHWAYS. ITS ACTION IS EXAGGERATED BY MUTATIONS ASSOCIATED WITH PARKINSON'S DISEASE AND CAN BE BLOCKED BY KINASE INHIBITORS. DISRUPTION OF THE GARP PROTEIN COMPLEX SENSITIZES DOPAMINERGIC NEURONS TO MUTANT LRRK2 TOXICITY IN C. ELEGANS, SHOWING THAT THESE PATHWAYS ARE INTERLINKED IN VIVO AND SUGGESTING A LINK IN PD (BEILINA ET AL., CELL REPORTS 31(5): 107614). THE LAB ALSO DEVELOPED A ROBUST PRECLINICAL MODEL OF PARKINSON'S DISEASE IN ADULT RATS HAVING NEURON-SPECIFIC EXPRESSION OF HUMAN LRRK2 BEARING THE G2019S MUTATION, WHICH INDUCES ROBUST DEGENERATION OF SUBSTANTIA NIGRA DOPAMINERGIC NEURONS. THIS MODEL SHOWED THAT SUCH NEURODEGENERATION REQUIRES NORMAL GTPASE AND KINASE ACTIVITY. INHIBITION OF THE KINASE AND ALTERATION OF GTPASE ACTIVITY MAY BE PROMISING AS DISEASE-MODIFYING TARGETS (NGUYEN ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA 117(29): 17296-17307). THE LAB ALSO PUBLISHED TWO REVIEWS, ONE ON THE FUNCTIONS OF LRRK2 WITH THE ENDOLYSOSOMAL PATHWAY (ERB AND MOORE, JOURNAL OF PARKINSON'S DISEASE 10(4): 1271-1291) AND ANOTHER ON THE LINKAGE BETWEEN LRRK2 AND PROTEIN AGGREGATION IN ANIMAL MODELS OF PARKINSON'S DISEASE (DUES AND MOORE, FRONTIERS IN NEUROSCIENCE 14:719). THE GUERREIRO AND BRAS LABS COLLABORATED ON PROJECTS IN SEVERAL DIVERSE AREAS. THE KCNN2 GENE IS HIGHLY EXPRESSED IN THE HUMAN BRAIN. ONE OF THEIR PAPERS REPORTED A MISSENSE MUTATION IN THAT GENE WHICH TRACKED WITH THE CHILDHOOD-ONSET TREMORS CHARACTERISTIC OF MYOCLONUS-DYSTONIA. THIS IS THE FIRST SUGGESTION THAT KCNN2 MUTATIONS COULD BE A PLAUSIBLE CAUSE OF THIS DISEASE (BALINT ET AL., EUROPEAN JOURNAL OF NEUROLOGY 27(8): 1471-1477). THE LABS ALSO PUBLISHED THE RESULTS OF WHOLE-EXOME SEQUENCING OF A COHORT OF 1118 CAUCASIAN PATIENTS WHO HAD DEMENTIA WITH LEWY BODIES (DLB); THEY FOCUSED ON GENES THAT CAUSE MONOGENIC NEURODEGENERATIVE DISEASES. THE RARITY OF PREVIOUSLY REPORTED PATHOGENIC MUTATIONS IN THIS COHORT SUGGESTS THAT THE GENETIC OVERLAP BETWEEN OTHER NEURODEGENERATIVE DISEASES AND DLB IS NOT SUBSTANTIAL (ORME ET AL. ACTA NEUROPATHOLOGICA COMMUNICATIONS 8(1): 5). A THIRD PAPER IDENTIFIED A NOVEL HOMOZYGOUS MISSENSE MUTATION OF THE MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) IN A PORTUGUESE FAMILY WITH EARLY-ONSET, AUTOSOMAL RECESSIVE, CEREBELLAR ATAXIA WITH NEUROPATHY AND OCULOMOTOR APRAXIA. THE MUTATION REDUCED PROTEIN STABILITY, IMPAIRED THE PROTEIN'S GLYCOSYLATION, AND CHANGED ITS SUBCELLULAR LOCATION. THIS MUTATION THUS PROVIDES A NEW DIAGNOSTIC MARKER FOR HEREDITARY OCCURRENCES OF THIS DISEASE (SANTOS ET AL., JOURNAL OF CLINICAL MEDICINE 9(4): 1212). THEY ALSO WORKED ON A STUDY OF GENETIC FRONTOTEMPORAL DEMENTIA, USING AN INTERNATIONAL, RETROSPECTIVE COHORT OF 3403 INDIVIDUALS FROM 1492 FAMILIES. IT SHOWED THAT THE AGE AT SYMPTOM ONSET AND AT DEATH OF PATIENTS IS INFLUENCED BY THEIR GENETIC GROUP, BY THE SPECIFIC MUTATION CARRIED, AND BY FAMILY MEMBERSHIP. THE DATA SUGGEST THAT STUDYING OTHER MEMBERS OF A FAMILY WILL BE HELPFUL ONLY FOR INDIVIDUALS WITH MUTATIONS OF THE MAPT GENE. (MOORE ET AL., LANCET NEUROLOGY 19(2): 145-156). THE LABRIE LAB REPORTED THAT NEURONS IN THE HUMAN PREFRONTAL CORTEX HAVE HEMISPHERIC DIFFERENCES IN DNA METHYLATION LARGELY MEDIATED BY DIFFERENTIAL CPH METHYLATION. THE ASYMMETRY IS GREATER IN NEURONS OF PARKINSON'S DISEASE PATIENTS THAN IN HEALTHY CONTROLS. THESE DIFFERENCES MAY AFFECT THE PROGRESSION AND SYMPTOMS OF PARKINSON'S DISEASE (LI ET AL., GENOME BIOLOGY 21: 61). IN ANOTHER PAPER, THE LABRIE, COETZEE, AND JOVINGE LABS FOUND A WIDESPREAD INCREASE IN CYTOSINE METHYLATION AT THE ENHANCER LOCI IN PARKINSON'S DISEASE NEURONS. PARKINSON'S PATIENTS SHOWED AN INCREASE IN TET2 GENE ACTIVITY, WHICH IS A MASTER REGULATOR OF CYTOSINE MODIFICATIONS. DECREASED TET2 ACTIVITY IS NEUROPROTECTIVE IN MICE AND MAY BE A NEW THERAPEUTIC AVENUE AGAINST PARKINSON'S DISEASE (WEILAND ET AL., NATURE NEUROSCIENCE 23(10): 1203-1214). |
| FORM 990, PART IX, COLUMN D | FUNDRAISING EXPENSES AT VARI WERE INCURRED TO SUPPORT THE MISSION OF THE RESEARCH INSTITUTE THROUGH DONOR SOLICITATION, GRANT SOLICITATION AND EXTRAMURAL PROPOSAL PREPARATION. |
| FORM 990, PART X, LINE 33 | VARI NET ASSETS ARE CONSIDERED ON A CONSOLIDATED BASIS WITH VAN ANDEL INSTITUTE (VAI)AND VAN ANDEL EDUCATION INSTITUTE (VAEI). ON A CONSOLIDATED BASIS, NET ASSETS ARE $1,635,281,000 PER AUDITED FINANCIAL STATEMENTS. THE NEGATIVE NET ASSET BALANCE AT VARI IS DUE TO VAI FUNDING EXPENSES ON A CASH BASIS AND THE UNREALIZED LOSS RECORDED IN ASSOCIATION WITH THE INTEREST RATE SWAP. |
Schedule R IRS990ScheduleR
Id Disregarded Entities IdDisregardedEntitiesGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Total IncomeTotalIncomeAmt | End Of Year AssetsEndOfYearAssetsAmt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|
| VAI INNOVATIONS LLC | |||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000823 | LICENSING INTELLECTUAL PROPERTY OF VARI | MI | $144,192 | $0 | VAN ANDEL RESEARCH INSTITUTE |
| BOSTWICK EVENT MANAGEMENT | |||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000823 | EVENT MANAGEMENT | MI | $5,426 | $118,506 | VAN ANDEL RESEARCH INSTITUTE |
| C3 LEARNING DEVELOPMENT LLC | |||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000823 | EDUCATIONAL PROGRAMS FOR K-12 STUDENTS AND TEACHERS | MI | $72,102 | $372,540 | VAN ANDEL RESEARCH INSTITUTE |
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Direct Controlling NADirectControllingNACd | Controlled OrganizationControlledOrganizationInd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt |
|---|---|---|---|---|---|---|---|---|---|---|---|
| VAN ANDEL INSTITUTE | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000820 | SUPPORTING ORGANIZATION FOR VARI AND VAEI | MI | 501(C)(3) | 12C | N/A | 0 | |
| VAN ANDEL EDUCATION INSTITUTE | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | MI | 495032518 | 522000824 | OPERATING A SCIENCE EDUCATION PROGRAM | MI | 501(C)(3) | 2 | Yes (1) | VAN ANDEL INSTITUTE | |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | |||||||||||
| 333 BOSTWICK AVENUE NE | GRAND RAPIDS | ME | 495032518 | 203340886 | OPERATING A GRADUATE SCHOOL | MI | 501(C)(3) | 2 | Yes (1) | VAN ANDEL EDUCATION INSTITUTE | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | Yes (1) | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | Yes (1) | SharingOfFacilitiesInd |
| Paid Employees Sharing | Yes (1) | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | Yes (1) | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | Yes (1) | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | Yes (1) | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (20 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| VAN ANDEL INSTITUTE | ||
| C | $54,223,134 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE | ||
| E | $99,600,000 | TOTAL RECORDED |
| VAN ANDEL INSTITUTE | ||
| N | $283,368 | ALLOCATION BASED ON SQ. FOOTAGE |
| VAN ANDEL INSTITUTE | ||
| P | $1,186,444 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE | ||
| N | $130,544 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| O | $1,092,310 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| P | $1,774,390 | ACTUAL AMOUNT PAID |
| VAN ANDEL EDUCATION INSTITUTE | ||
| Q | $2,360,200 | ACTUAL AMOUNT RECEIVED |
| VAN ANDEL EDUCATION INSTITUTE | ||
| N | $32,941 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| O | $275,630 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| N | $3,965 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| N | $159,394 | ALLOCATION BASED ON SQ. FOOTAGE |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| Q | $305,904 | ACTUAL AMOUNT RECEIVED |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| O | $33,178 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| Q | $6,975,460 | ACTUAL AMOUNT RECEIVED |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| P | $222,083 | ACTUAL AMOUNT PAID |
| VAN ANDEL INSTITUTE GRADUATE SCHOOL | ||
| O | $188,875 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| O | $17,664 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL INSTITUTE | ||
| O | $85,772 | ALLOCATION BASED ON EFFORT |
| VAN ANDEL EDUCATION INSTITUTE | ||
| S | $213,714 | NET ASSETS RECEIVED |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | SCHEDULE R, PART V, LINE 2 (20) | FormAndLineReferenceDesc |
| Explanation | THIS AMOUNT REPRESENTS NET ASSETS OF $213,714 TRANSFERRED FROM VAN ANDEL EDUCATION INSTITUTE FOR C3 LEARNING DEVELOPMENT, LLC. | ExplanationTxt |
Comments